Latest news and press releases about Capricor Therapeutics, Inc. (CAPR): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
Price
| Price | $8.56 |
| Market Cap | $492M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 1.85 |
| EV / EBITDA | 0.52 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -56.60% |
| Return on Invested Capital | -40.08% |
| Return on Assets | -35.10% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACHV · ALLO · ARCT · CABA · EDIT · IMMP · LXEO
Explore sector: Healthcare · Biotechnology
More sections of CAPR: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks